The autoimmune hemolytic anemia ICD 10 code is D59.1 — specifically categorized as “Other autoimmune hemolytic anemias” under the World Health Organization’s International Classification of Diseases, 10th Revision. If you’re a coder, clinician, or patient trying to pin down the right code, D59.1 is your primary answer. But the full picture is more nuanced than a single code, and getting it wrong can cause claim denials or misrepresent clinical severity.
AIHA isn’t one disease — it’s a group of conditions where the immune system produces antibodies that attack and destroy your own red blood cells. The specific ICD-10 code you need depends on the subtype, whether it’s primary or secondary, and whether a drug triggered it. Let’s break all of this down.
Complete ICD-10 Codes for Autoimmune Hemolytic Anemia
While D59.1 is the most commonly cited code, several related codes exist depending on the clinical scenario. Using the wrong one can lead to billing problems or incomplete medical records.
| ICD-10 Code | Description | When to Use |
|---|---|---|
| D59.0 | Drug-induced autoimmune hemolytic anemia | AIHA triggered by medications (e.g., methyldopa, penicillin, cephalosporins) |
| D59.1 | Other autoimmune hemolytic anemias | Primary (idiopathic) warm or cold AIHA not caused by drugs |
| D59.10 | Autoimmune hemolytic anemia, unspecified | AIHA type not yet determined |
| D59.11 | Warm autoimmune hemolytic anemia | IgG-mediated AIHA reactive at body temperature (37°C) |
| D59.12 | Cold autoimmune hemolytic anemia | IgM-mediated cold agglutinin disease (reactive at 0–4°C) |
| D59.13 | Mixed type autoimmune hemolytic anemia | Both warm and cold antibodies present |
| D59.2 | Drug-induced nonautoimmune hemolytic anemia | Drug-related hemolysis without autoimmune mechanism |
Coding tip: If AIHA is secondary to another condition — such as systemic lupus erythematosus (M32.x) or chronic lymphocytic leukemia (C91.1x) — code the underlying condition as the primary diagnosis and D59.1 as secondary. This matters for reimbursement.
Warm vs. Cold AIHA: Why the Distinction Matters for Coding
Warm AIHA accounts for roughly 70–80% of all AIHA cases. It’s driven by IgG antibodies that bind to red blood cells at normal body temperature (37°C), tagging them for destruction primarily in the spleen. Hemoglobin levels can drop to 5–7 g/dL in acute episodes — well below the normal range of 12–16 g/dL for women and 14–18 g/dL for men.
Cold agglutinin disease (CAD) makes up about 15–25% of cases. Here, IgM antibodies activate complement at lower temperatures (typically below 30°C), causing red blood cell destruction mainly in the liver. Patients often notice symptoms worsening in cold environments — bluish fingers, fatigue after cold exposure, and dark urine.
Mixed-type AIHA is rare (roughly 5–8% of cases) but clinically aggressive, with both IgG and IgM antibodies present. These patients tend to have more severe anemia and are harder to treat.
How AIHA Is Diagnosed
The diagnostic workup hinges on the Direct Antiglobulin Test (DAT), also called the Direct Coombs test. A positive DAT confirms that antibodies or complement proteins are bound to the red blood cell surface. Roughly 95% of AIHA patients test positive on DAT, though DAT-negative AIHA exists and represents about 5–10% of cases.
Beyond the DAT, clinicians look for a specific pattern of lab findings:
| Lab Test | Expected Finding in AIHA | Why It Matters |
|---|---|---|
| Hemoglobin | Low (often <10 g/dL) | Confirms anemia severity |
| Reticulocyte count | Elevated (>2%) | Bone marrow compensating for RBC loss |
| Indirect bilirubin | Elevated | Byproduct of RBC breakdown |
| Haptoglobin | Low or undetectable | Consumed during hemolysis |
| LDH (lactate dehydrogenase) | Elevated | Released from destroyed RBCs |
| Peripheral blood smear | Spherocytes, polychromasia | Visual confirmation of hemolysis |
| Direct Coombs test (DAT) | Positive (IgG, C3d, or both) | Confirms autoimmune mechanism |
Common Causes and Triggers
About 50% of AIHA cases are primary (idiopathic) — meaning no underlying cause is identified. The other half are secondary to:
- Autoimmune diseases: Systemic lupus erythematosus (most common), rheumatoid arthritis, Sjögren syndrome
- Lymphoproliferative disorders: Chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma
- Infections: Mycoplasma pneumoniae and Epstein-Barr virus (especially for cold type)
- Medications: Methyldopa, penicillin, cephalosporins, fludarabine (use D59.0 for drug-induced cases)
Treatment Overview
First-line treatment for warm AIHA is corticosteroids — typically prednisone at 1–1.5 mg/kg/day. About 70–85% of patients respond initially, though relapse rates are high (up to 50% once steroids are tapered).
For steroid-refractory or relapsing cases, options include rituximab (anti-CD20 monoclonal antibody), splenectomy, or immunosuppressants like mycophenolate mofetil. Rituximab has become increasingly popular as a steroid-sparing second-line agent, with response rates around 70–80%.
Cold agglutinin disease responds poorly to steroids and splenectomy. Rituximab is the preferred first-line therapy for CAD, and the complement inhibitor sutimlimab (Enjaymo) was FDA-approved in 2022 specifically for CAD — the first targeted therapy for this condition.
When to See a Doctor
Seek medical attention if you experience:
- Unexplained fatigue with pale or yellowish skin
- Dark brown or cola-colored urine
- Rapid heart rate or shortness of breath with minimal exertion
- Recurrent episodes of these symptoms, especially triggered by cold
If you’ve already been diagnosed with AIHA and your hemoglobin drops below 7 g/dL, or you develop chest pain or severe dizziness, go to the emergency department. Acute hemolytic crises can be life-threatening.
Frequently Asked Questions
Is autoimmune hemolytic anemia the same as D59.1?
D59.1 covers most non-drug-induced AIHA, but the ICD-10-CM now includes more specific subcodes: D59.11 for warm AIHA, D59.12 for cold AIHA, and D59.13 for mixed type. Use D59.10 if the type is unspecified. Drug-induced AIHA is coded separately as D59.0.
Can AIHA be coded as a primary diagnosis?
Yes — when AIHA is idiopathic (no underlying disease), D59.1 or its subcodes serve as the primary diagnosis. When AIHA is secondary to lupus or CLL, code the underlying condition first and AIHA second.
What is the life expectancy with autoimmune hemolytic anemia?
Primary warm AIHA generally has a good prognosis. A 2020 study in Blood found that most patients achieve remission with treatment, though relapses are common. Five-year survival for primary AIHA exceeds 90%. Secondary AIHA prognosis depends heavily on the underlying condition — AIHA associated with CLL or lymphoma carries a worse outlook.
Does cold agglutinin disease have a different ICD-10 code?
Yes. Cold agglutinin disease should be coded as D59.12 (Cold autoimmune hemolytic anemia). Previously, it fell under the broader D59.1 umbrella, but updated ICD-10-CM coding provides this more specific option.
Why does the ICD-10 code matter for AIHA patients?
Accurate coding affects insurance coverage, prior authorization for biologics like rituximab or sutimlimab, disability documentation, and clinical research tracking. An incorrect code can delay treatment approvals or result in claim denials.
